Ernesto P. Korbenfeld
Buenos Aires, C, Argentina
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 04, 2026
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 09, 2026
Efficacy and safety of subcutaneous and intravenous administration of atezolizumab in patients with non-small cell lung cancer, including early-stage, locally advanced or metastatic disease: Updated results of the IMscin001 and IMscin002 randomized studies.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 09, 2026
Overall Survival with Amivantamab-Lazertinib in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: September 09, 2025
Exploratory Analyses of Patient Preferences for Atezolizumab Subcutaneous Versus Intravenous from the IMscin002 Study in Patients with Non-Small Cell Lung Cancer.
Journal: Oncology and therapy
Published: June 23, 2025
Erratum to 'Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC' [JTO Clinical and Research Reports Volume 6 Issue 5 (2025) 100815].
Journal: JTO clinical and research reports
Published: June 19, 2025
Treatment Trends in Metastatic Renal Clear Cell Carcinoma in Argentina.
Journal: JCO global oncology
Published: April 23, 2025
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: March 05, 2025
Lazertinib Versus Osimertinib in Previously Untreated EGFR-Mutant Advanced NSCLC: A Randomized, Double-Blind, Exploratory Analysis From MARIPOSA.
Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Published: February 28, 2025
Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: January 03, 2025
Primary Results from IMscin002: A Study to Evaluate Patient Preferences and Perceptions of Health Care Professionals for Atezolizumab Subcutaneous Versus Intravenous for the Treatment of NSCLC.
Journal: JTO clinical and research reports
Published: November 21, 2024
Latin American Challenges and Recommendations for Poly Adenosine Diphosphate Ribose Polymerase Inhibitor Treatment in Metastatic Castration Resistant Prostate Cancer: An Expert Overview.
Journal: Cancer control : journal of the Moffitt Cancer Center
Published: October 10, 2024
Last Updated: 09/26/2026